Understanding Combined Immunodeficiency with Granulomas
At a Glance
Combined immunodeficiency with granulomas is a rare immune disorder that can cause recurrent infections, granulomas, and autoimmunity. Partial-function RAG or Artemis gene changes may delay symptoms, while immune and genetic testing guide treatment such as immunoglobulin therapy or HSCT.
Receiving a diagnosis like combined immunodeficiency with granulomas (and/or autoimmunity) can feel overwhelming, especially after a long search for answers. This diagnosis often explains a history of frequent infections alongside symptoms like skin lesions or inflammation that didn’t seem to fit a standard pattern. While it is a serious condition, finally having a name for it is a critical turning point that opens the door to a clear, established treatment path [1][2].
Understanding the “Middle Ground”
Combined immunodeficiency with granulomas is not one identical disease, but a heterogeneous spectrum. It is a rare, delayed-onset form of an inborn error of immunity (a genetic condition that affects how the immune system is built). It is most often caused by changes in the RAG (Recombination-Activating Genes) or Artemis (DCLRE1C) genes, though other genes can also be responsible [3][4].
In the most severe form of this condition, called SCID (Severe Combined Immunodeficiency), these genes have no function at all, which typically leads to critical illness in the first months of life. In this spectrum, however, the genetic variants are hypomorphic—meaning they have “partial function” [2][5]. This partial function allows the immune system to partially develop, which is why the diagnosis is often delayed until later in childhood or even adulthood [4][6].
Why the Immune System is Dysregulated
The core mechanism is a delicate imbalance where the immune system is both too weak and improperly targeted [1].
- Immune Deficiency (Too Weak): Because the RAG or Artemis genes only work partially, your body cannot create a diverse “library” of T cells and B cells [7][8]. This makes it harder for the immune system to recognize and fight off specific germs, leading to recurrent infections.
- Immune Dysregulation (Improperly Targeted): The few immune cells that do develop are often poorly regulated. They may fail to recognize the difference between “invader” and “self,” leading the body to attack its own tissues (autoimmunity) [9][10].
- Granulomas: These are small areas of inflammation that the body creates when it is trying to wall off a perceived threat it cannot fully eliminate [11]. They often appear as nodules on the skin or within internal organs like the spleen. Research has found that in some cases, these granulomas may contain traces of common viruses, such as the rubella virus, which the immune system is struggling to clear [4][11].
How Rare is This?
Because this condition is a clinical spectrum, there is no single number for how often it occurs. To provide context:
- RAG deficiency (of all types, including SCID) is estimated to occur in roughly 1 in 180,000 to 1 in 300,000 births based on regional studies [1].
- In one large worldwide study of 60 patients with hypomorphic RAG mutations selected for transplantation, about 18% had granulomas before transplant and 72% had at least one autoimmune symptom [12].
Clarifying Common Misunderstandings
Because this condition is so rare, it is frequently misdiagnosed in its early stages. Common misunderstandings include:
- “It can’t be a severe immune defect because it started late”: Many doctors expect these genetic defects to show up in infancy. Because your/your child’s genes have partial function, symptoms may not appear until later, which can lead to years of searching for the right diagnosis [2][4].
- “It’s just sarcoidosis or isolated autoimmunity”: Because granulomas and autoimmunity are the most visible symptoms, the underlying immune deficiency is sometimes missed [4].
- “The T-cell counts look okay, so the immune system is fine”: The number of immune cells might look near normal in a standard blood test, but the quality and diversity of those cells are restricted [13][8]. Special tests, like checking naïve T cells or T-cell receptor repertoire, are needed to see the real picture [2][7].
What This Diagnosis Means (and Does Not Mean)
Finding a genetic variant requires careful interpretation by specialists:
- Carrier Status: Carrying one copy of a recessive RAG or Artemis mutation does not cause this disease.
- Variant of Uncertain Significance (VUS): Sometimes genetic testing finds a change that has never been seen before. A VUS requires functional testing to prove whether it actually causes the disease.
- Family Planning: Because these are genetic conditions, you should be referred for genetic counseling to discuss whether siblings or parents should be tested.
The path to diagnosis often involves advanced genetic testing, such as Next-Generation Sequencing (NGS), to identify the specific variants [14][2]. Once confirmed, your medical team can move from treating individual infections to a more comprehensive plan. This may include immunoglobulin replacement, medications to calm the overactive part of the immune system, and, in some cases, a curative path like a Hematopoietic Stem Cell Transplant (HSCT). Having a name for this condition means you are no longer managing a mystery, but a known medical challenge with a community of specialists ready to help.
Common questions in this guide
What is combined immunodeficiency with granulomas?
Why can symptoms start in childhood or adulthood instead of infancy?
Which genes are linked to combined immunodeficiency with granulomas?
How is combined immunodeficiency with granulomas diagnosed?
What treatments may be used for this immune disorder?
Do granulomas mean the condition is sarcoidosis?
Can one parent pass on a RAG or Artemis variant without having the disease?
Get notified when new evidence is published on Combined immunodeficiency with granulomatosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
The Clinical and Genetic Spectrum of 82 Patients With RAG Deficiency Including a c.256_257delAA Founder Variant in Slavic Countries.
Sharapova SO, Skomska-Pawliszak M, Rodina YA, et al.
Frontiers in immunology 2020; (11()):900 doi:10.3389/fimmu.2020.00900.
PMID: 32655540 - 2
Approaches to patients with variants in RAG genes: from diagnosis to timely treatment.
Bulkhi AA, Dasso JF, Schuetz C, Walter JE
Expert review of clinical immunology 2019; (15(10)):1033-1046 doi:10.1080/1744666X.2020.1670060.
PMID: 31535575 - 3
Clinical Manifestations, Mutational Analysis, and Immunological Phenotype in Patients with RAG1/2 Mutations: First Cases Series from Mexico and Description of Two Novel Mutations.
Lugo-Reyes SO, Pastor N, González-Serrano E, et al.
Journal of clinical immunology 2021; (41(6)):1291-1302 doi:10.1007/s10875-021-01052-0.
PMID: 33954879 - 4
Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency.
Walter JE, Rosen LB, Csomos K, et al.
The Journal of clinical investigation 2015; (125(11)):4135-48.
PMID: 26457731 - 5
Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency.
Felgentreff K, Lee YN, Frugoni F, et al.
The Journal of allergy and clinical immunology 2015; (136(1)):140-150.e7.
PMID: 25917813 - 6
Variable clinical presentation of hypomorphic DCLRE1C deficiency from childhood to adulthood.
Hazar E, Karaselek MA, Kapakli H, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2024; (35(10)):e14260 doi:10.1111/pai.14260.
PMID: 39425552 - 7
Characterization of T and B cell repertoire diversity in patients with RAG deficiency.
Lee YN, Frugoni F, Dobbs K, et al.
Science immunology 2016; (1(6)) doi:10.1126/sciimmunol.aah6109.
PMID: 28783691 - 8
DCLRE1C (ARTEMIS) mutations causing phenotypes ranging from atypical severe combined immunodeficiency to mere antibody deficiency.
Volk T, Pannicke U, Reisli I, et al.
Human molecular genetics 2015; (24(25)):7361-72 doi:10.1093/hmg/ddv437.
PMID: 26476407 - 9
Immune dysregulation in patients with RAG deficiency and other forms of combined immune deficiency.
Delmonte OM, Villa A, Notarangelo LD
Blood 2020; (135(9)):610-619 doi:10.1182/blood.2019000923.
PMID: 31942628 - 10
Hypomorphic Rag1 mutations alter the preimmune repertoire at early stages of lymphoid development.
Ott de Bruin LM, Bosticardo M, Barbieri A, et al.
Blood 2018; (132(3)):281-292 doi:10.1182/blood-2017-12-820985.
PMID: 29743177 - 11
Rubella-associated granuloma in a patient with a compound heterozygous RAG1 defect and review of the literature.
Akarsu A, Sonmez G, Schiefer AI, et al.
Immunologic research 2025; (73(1)):150 doi:10.1007/s12026-025-09711-9.
PMID: 41139764 - 12
Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT.
Schuetz C, Gerke J, Ege M, et al.
Blood 2023; (141(7)):713-724 doi:10.1182/blood.2022017667.
PMID: 36279417 - 13
RAG1 deficiency may present clinically as selective IgA deficiency.
Kato T, Crestani E, Kamae C, et al.
Journal of clinical immunology 2015; (35(3)):280-8 doi:10.1007/s10875-015-0146-4.
PMID: 25739914 - 14
Targeted Next-Generation Sequencing in the Molecular Diagnosis of Severe Combined Immunodeficiency.
Bakaros E, Sarrou S, Gkantaras A, et al.
Medicina (Kaunas, Lithuania) 2025; (61(9)) doi:10.3390/medicina61091644.
PMID: 41011036
This page is for informational purposes only and does not constitute medical advice. An immunologist and genetics team should interpret your genetic and immune testing and discuss treatment for you or your child.